• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [53 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2024 Basque Office for Health Technology Assessment (OSTEBA) [Use of self-sampling for the detection of human papillomavirus in cervical cancer screening]
2022 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2020 NIHR Health Technology Assessment programme Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020 Canary Health Service [HPV vaccination in adolescent boys: cost-effectiveness and budget impact]
2019 Canadian Agency for Drugs and Technologies in Health (CADTH) HPV testing for primary cervical cancer screening: a health technology assessment
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: pharmacological treatment of sexually transmitted and blood-borne infections ─ external condylomas (anogenital warts)]
2019 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2018 NIHR Health Technology Assessment programme Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation
2017 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: comparison of cervical cancer screening strategies involving the human papillomavirus screening test (HPV test) or gynecological cytology (Pap test)]
2017 Health Information and Quality Authority (HIQA) Health technology assessment of human papillomavirus testing as the primary screening method for prevention of cervical cancer
2017 Adelaide Health Technology Assessment (AHTA) Serious adverse events associated with HPV vaccination
2016 HAYES, Inc. 5-aminolevulinic acid photodynamic therapy versus carbon dioxide laser ablation for the treatment of condylomata acuminata
2016 HAYES, Inc. Carbon dioxide (CO2) laser ablation versus other surgical treatment of condylomata acuminata
2016 NIHR Health Technology Assessment programme UNderstanding uptake of Immunisations in TravellIng aNd Gypsy communities (UNITING): a qualitative interview study
2016 Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2015 Belgian Health Care Knowledge Centre (KCE) Cervical cancer screening program and Human Papillomavirus (HPV) testing, part II: Update on HPV primary screening
2014 Medical Services Advisory Committee (MSAC) National Cervical Screening Program renewal
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Benefit assessment of an HPV test in primary screening for cervical cancer - Rapid report]
2014 NIHR Health Technology Assessment programme The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds
2013 National Evidence-based Healthcare Collaborating Agency (NECA) [Cost-effectiveness of human papillomavirus vaccination in South Korea]
2012 HAYES, Inc. Human papillomavirus (HPV) genotyping to test for the presence of HPV 16 and 18 in women
2012 Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of human papillomavirus (HPV) testing, followed by liquid-based cytology triage of positive results, in primary screening for cervical cancer?
2012 Scottish Health Technologies Group (SHTG) High-risk human papillomavirus (HPV) testing as triage for women with mild or borderline cytology abnormalities
2010 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Detection of high risk human papillomavirus E6 and E7 oncogenes for cervical cancer screening]
2010 Health Services Assessment Collaboration (HSAC) The role of high-risk human papillomavirus testing for managing women with glandular abnormalities on cytology
2009 Institute of Health Economics (IHE) Human papillomavirus (HPV) testing in Alberta
2009 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors]
2009 Institute of Health Economics (IHE) Human papillomavirus (HPV) testing in Alberta
2009 Adelaide Health Technology Assessment (AHTA) Cervista HPV 16/18 for the identification of strains of the human papillomavirus associated with cervical cancer
2009 NIHR Health Technology Assessment programme ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening
2008 Health Information and Quality Authority (HIQA) The role of human papillomavirus vaccines in reducing the risk of cervical cancer in Ireland
2007 New Zealand Health Technology Assessment (NZHTA) Performance of commercially available HPV tests
2007 Medical Advisory Secretariat (MAS) Anal dysplasia screening: an evidence-based analysis
2007 Andalusian Health Technology Assessment Area (AETSA) [Vaccine for primary prophylaxis against human papillomavirus infection]
2007 Canadian Agency for Drugs and Technologies in Health (CADTH) Human papillomavirus (HPV) vaccines: A Canadian update
2007 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment]
2006 HAYES, Inc. Human papillomavirus vaccines for prevention of cervical cancer
2006 Institute for Clinical Effectiveness and Health Policy (IECS) Efficacy of the human papillomavirus (HPV) vaccine
2006 HAYES, Inc. Human papillomavirus vaccines for prevention of cervical cancer
2006 Belgian Health Care Knowledge Centre (KCE) Cervical cancer screening and Human Papillomavirus (HPV) testing
2005 Institute for Clinical Systems Improvement (ICSI) HPV DNA testing for the screening and monitoring of cervical cancer
2005 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [The use of liquid based cytology (LBC) and conventional pap smear (CPS) for cervical screening in Denmark]
2005 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for prevention of human papillomavirus infection
2004 Medical Services Advisory Committee (MSAC) The use of human papillomavirus testing to monitor effectiveness of treatment of high-grade intraepithelial abnormalities of the cervix
2003 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Liquid-based cytology and human papillomavirus testing in cervical cancer screening
2003 Medical Services Advisory Committee (MSAC) Human papillomavirus testing for cervical screening
2002 Medical Services Advisory Committee (MSAC) Human papillomavirus testing in women with cytological prediction of low-grade abnormality
2001 The Swedish Council on Health Technology Assessment (SBU) Human papillomavirus testing in primary cervical cancer screening - early assessment briefs (ALERT)
2001 Institute for Clinical Systems Improvement (ICSI) HPV DNA testing for cervical cancer
2001 ECRI Human papillomavirus DNA testing for diagnosis of cervical dysplasia and carcinoma
2000 NIHR Health Technology Assessment programme Liquid-based cytology in cervical screening: a rapid and systematic review
1999 NIHR Health Technology Assessment programme A systematic review of the role of human papillomavirus testing within a cervical screening programme
1993 The Swedish Council on Health Technology Assessment (SBU) Genetic diagnosis by PCR